Abstract Number: 1114 • 2019 ACR/ARP Annual Meeting
Survival and Cost of Biologic DMARDs in a Military Medical Center: A Quality Improvement Initiative
Background/Purpose: High drug costs and lack of transparency of these costs is a major concern in the United States. Biologic therapy for rheumatoid arthritis (RA)…Abstract Number: 2731 • 2019 ACR/ARP Annual Meeting
Decomposition Analysis of Spending and Price Trends for Biologic Anti-Rheumatic Drugs in Medicare and Medicaid
Background/Purpose: Billions of public dollars are spent each year on biologic disease-modifying anti-rheumatic drugs (bDMARDs), but the drivers of bDMARD spending and per-patient cost increases…Abstract Number: 2889 • 2019 ACR/ARP Annual Meeting
From a Potential Solution to Part of the Problem: Analysis of Spending and Price Trends for Brand-Name and Generic Colchicine and Other Gout Medications
Background/Purpose: Gout affects >4 million US adults aged ≥ 65 years, but little is known about the scale and drivers of public spending on gout…Abstract Number: 1043 • 2017 ACR/ARHP Annual Meeting
Comparison of the Costs for Hyaluronic Acid and Total Knee Arthroplasty in the Treatment of OA for the Blue Cross/Blue Shield Patient Population
Background/Purpose: Previous HA studies have focused on the Medicare population, but less is known of the treatment patterns and cost of HA relative to knee…Abstract Number: 1097 • 2017 ACR/ARHP Annual Meeting
Investigating Opportunities for Cost Conscious Care: A Review of Physician Practice in Ordering Anti-Nuclear Antibody Testing at an Academic Community Hospital
Background/Purpose: More than 94,000 ANA tests are performed each year resulting in an estimated cost of 2.24 million dollars annually. The American College of Rheumatology…Abstract Number: 1885 • 2017 ACR/ARHP Annual Meeting
Epidemiology of Hospitalized Adult Onset Still’s Disease in United States
Background/Purpose: There is a dearth of epidemiological studies on Adult Onset Still’s Disease (AOSD) and no consensus on its incidence and prevalence. Most studies report…Abstract Number: 114 • 2017 ACR/ARHP Annual Meeting
Early Diagnosis and Treatment of RA: Clinical Performance and Economic Outcomes from a Continuing Education Initiative
Background/Purpose: The CME initiative RAPID® (Rheumatoid Arthritis: Primary Care Initiative for Improved Diagnosis and Outcomes) is a 7-year series of activities that used national-scope aggregated…Abstract Number: 1294 • 2015 ACR/ARHP Annual Meeting
Infection and Screening Costs Related to Tumor Necrosis Factor-Alpha Inhibitor Use
Background/Purpose: Bacterial and fungal infections (e.g., tuberculosis, histoplasmosis) have been associated with the use of TNF-α inhibitors (TNFI). Although screening for specific infections prior to…Abstract Number: 1971 • 2015 ACR/ARHP Annual Meeting
Healthcare Utilization and Direct Medical Costs of Giant Cell Arteritis
Title: Healthcare Utilization and Direct Medical Costs of Giant Cell Arteritis Background/Purpose: Giant cell arteritis (GCA) is the most common systemic vasculitis in patients aged…Abstract Number: 2105 • 2015 ACR/ARHP Annual Meeting
Drug Survival and Cost Effectiveness in Patients on Reduced Dose Anti-TNF: Results of a 4 Year Prospective Observational Study
Background/Purpose: Anti-TNF-α drugs are effective treatments for patients with inflammatory arthritis (IA). They are however expensive and their use carries a significant cost burden to…Abstract Number: 2486 • 2015 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Quality Measures – Automated Display of Care Gaps and Capture of Physician Decision Making at the Clinic Visit
Background/Purpose: Rheumatoid Arthritis (RA) quality measures evaluate performance, and thus do not by themselves result in improvement. The ideal system to improve quality would provide…Abstract Number: 2632 • 2014 ACR/ARHP Annual Meeting
The Cornerstone to Reasonable Allocation of Health Resource: Valuation of Health Utility in Systemic Lupus Erythematosus
Background/Purpose: In a time of increasing economic constraints, it is crucial that health systems optimize their resource use to ensure that they generate the maximum…Abstract Number: 2277 • 2014 ACR/ARHP Annual Meeting
Inpatient Pediatric Rheumatic Diseases: Characteristics, Cost and Trends
Background/Purpose: Childhood rheumatic diseases (cRD) have wide spectrum of complexity and disease course from mild disease to acute fulminate disease and even sudden death. Physicians…Abstract Number: 2232 • 2014 ACR/ARHP Annual Meeting
Cost-Effectiveness of Glucosamine, Chondroitin Sulfate, Their Combination, Celecoxib,Non-Selective Non-Steroidal Anti-Inflammatory Drugs, and Placebo in Treating Knee Osteoarthritis
Background/Purpose: Knee osteoarthritis (KOA) affects 13.8% of the US population aged ≥26, causing significant burden-of-illness. We compared the cost-effectiveness of conventional medicines such as non-steroidal…Abstract Number: 1857 • 2014 ACR/ARHP Annual Meeting
Determinants of Annual Healthcare Utilization and Overall Cost of Care in Individuals with Systemic Lupus Erythematosus in a Large Insurance Claims Database: Glucocorticoid Use
Background/Purpose: Newer therapeutic agents in systemic lupus erythematosus (SLE) may increase cost of care but their effect on limiting the duration and the dosage of…
ACR Meeting Abstracts